Brii Biosciences Announces Agreement to Acquire VBI’s IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Brii Biosciences Limited (“Brii Bio,” “we,” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that it has entered into agreements with VBI Vaccines, Inc….
Monteris Medical Announces Extended Aetna® Coverage of its NeuroBlate® System Laser Interstitial Thermal Therapy for Brain Tumor Patients
Monteris Medical, the leader in minimally invasive image-guided laser interstitial thermal therapy (LITT), announced today that health insurance provider Aetna has updated its medical policy and will provide coverage to its beneficiaries with recurrent brain metastases, radiation necrosis and recurrent…
Beactica Therapeutics announces the selection of BEA-17 as a preclinical candidate
Beactica Therapeutics AB, the Swedish precision oncology company, today announced the selection of BEA-17 as a preclinical candidate for its LSD1 programme aimed at finding new therapies for aggressive brain tumours and other life-threatening cancers. BEA-17 is a first-in-class small…
